Role of Iron Sequestration in the Development of Anemia of CKD: Implications for Treatment Resistance

Background: Anemia is a common complication of CKD, and iron supplementation is the recommended first line of therapy. The efficacy of oral iron therapy in CKD is unsatisfactory, likely owing, at least in part, to elevated hepcidin. Hepcidin induction might limit iron availability for erythropoiesis through either reduced intestinal absorption or by enhanced sequestration. However, the relative contribution of iron malabsorption vs. sequestration to anemia of CKD remains unclear. Methods: CKD was induced in 8-week old wild type (WT) and macrophage-specific (LysM-Cre) ferroportin (Fpt) knockout (KO) mice using a 0.2% adenine diet for 8 weeks. We used oral carbonyl iron, iron sulfate, and iron citrate in doses comparable to those used in CKD patients. Iron content was quantified in the bone marrow, spleen, and liver by staining, a bathophenanthroline-based colorimetric method, and by MRI. Tissue ferritin was assessed by immunoblotting. Results: WT CKD mice developed anemia and their serum hepcidin was 3-fold higher than in healthy mice. There was a marked increase in the number of iron-positive cells in the bone marrow (Fig.) and a 2-fold increase in the spleen of WT CKD mice compared to healthy mice. Liver ferritin was induced in untreated WT CKD mice. Macrophage-specific Fpt KO CKD mice had more severe anemia and further increase of iron stores in the bone marrow, spleen, and liver, compared to WT CKD mice. Oral iron supplementation improved hemoglobin in WT CKD mice by 20.8% but increased hepcidin by 1.5-fold, spleen iron content by 74.8% and liver iron content by 12.5-fold compared to untreated CKD mice. Conclusion: In this model of CKD, we observed iron sequestration in the bone marrow, spleen, and liver in the absence of iron therapy. Oral iron supplementation further enhanced iron sequestration, disproportionate to the alleviation of anemia in CKD mice. Sequestered iron remained partially mobilizable via incompletely suppressed ferroportin. Funding: NIDDK Support, Private Foundation SupportBone marrow iron staining by Perls Prussian blue in healthy mice and in mice with untreated CKD after 8 weeks of control or adenine diet.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024cxdydhwx
Primary Topic
Erythropoietin and Anemia Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Role of Iron Sequestration in the Development of Anemia of CKD: Implications for Treatment Resistance

Chantalle A. Campbell, Mary E. Choi, Oleh M. Akchurin, Edwin Patiño et al.
Journal of the American Society of Nephrology
Erythropoietin and Anemia Treatment
article

Role of Iron Sequestration in the Development of Anemia of CKD: Implications for Treatment Resistance

Chantalle A. Campbell, Mary E. Choi, Oleh M. Akchurin, Edwin Patiño, Heba M. El-Sayed, Kanza Baqai, Jade Matthews balcombe, Hannah Glenn Federman
article en

Abstract

Background: Anemia is a common complication of CKD, and iron supplementation is the recommended first line of therapy. The efficacy of oral iron therapy in CKD is unsatisfactory, likely owing, at least in part, to elevated hepcidin. Hepcidin induction might limit iron availability for erythropoiesis through either reduced intestinal absorption or by enhanced sequestration. However, the relative contribution of iron malabsorption vs. sequestration to anemia of CKD remains unclear. Methods: CKD was induced in 8-week old wild type (WT) and macrophage-specific (LysM-Cre) ferroportin (Fpt) knockout (KO) mice using a 0.2% adenine diet for 8 weeks. We used oral carbonyl iron, iron sulfate, and iron citrate in doses comparable to those used in CKD patients. Iron content was quantified in the bone marrow, spleen, and liver by staining, a bathophenanthroline-based colorimetric method, and by MRI. Tissue ferritin was assessed by immunoblotting. Results: WT CKD mice developed anemia and their serum hepcidin was 3-fold higher than in healthy mice. There was a marked increase in the number of iron-positive cells in the bone marrow (Fig.) and a 2-fold increase in the spleen of WT CKD mice compared to healthy mice. Liver ferritin was induced in untreated WT CKD mice. Macrophage-specific Fpt KO CKD mice had more severe anemia and further increase of iron stores in the bone marrow, spleen, and liver, compared to WT CKD mice. Oral iron supplementation improved hemoglobin in WT CKD mice by 20.8% but increased hepcidin by 1.5-fold, spleen iron content by 74.8% and liver iron content by 12.5-fold compared to untreated CKD mice. Conclusion: In this model of CKD, we observed iron sequestration in the bone marrow, spleen, and liver in the absence of iron therapy. Oral iron supplementation further enhanced iron sequestration, disproportionate to the alleviation of anemia in CKD mice. Sequestered iron remained partially mobilizable via incompletely suppressed ferroportin. Funding: NIDDK Support, Private Foundation SupportBone marrow iron staining by Perls Prussian blue in healthy mice and in mice with untreated CKD after 8 weeks of control or adenine diet.

Journal of the American Society of NephrologyVol. 35(10S)
Cornell University (US), Weill Cornell Medicine (US)
Zero hunger
Openalex Percentile: Top 69%
Erythropoietin and Anemia Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.